Resources, Redundancy & Resilience: Overcoming Risk In Cell And Gene Production

By Nandu Deorkar, Senior Vice President, Biopharma Production Research & Development for Avantor

The clinical development of viral vector gene therapies has outpaced CMC, manufacturing, and formulation development creating process challenges that impact quality and shelf-life. This state of flux presents unique opportunities to de-risk the cell and gene manufacturing processes. Mitigating risk in cell and gene therapy requires a true manufacturing partner that can collaborate for continuous improvement, and not just a vendor of supplies.

To meet the speed to market demands of today requires process standardization and portability, improvements in raw material supply and sourcing and greater supply chain control. Read more from Avantor’s top innovator, Dr. Nandu Deokar, on strategies to increase resilience and overcome process challenges in cell and gene therapy production.